Therapeutic Cancer Vaccines Market to 2019

1

Therapeutic Cancer Vaccines Market to 2019 -
Pipeline Indicates Safer Treatments and Extended
Patient Survival, though High Prices May Limit
Uptake

Published By GBI Research
Published March - 2013
2
Description


GBI Research, the leading business intelligence
provider, has released its latest research
Therapeutic Cancer Vaccines Market to 2019 -
Pipeline Indicates Safer Treatments and Extended
Patient Survival, though High Prices May Limit
Uptake. There is currently only one marketed
therapeutic cancer vaccine, Provenge, which is
indicated for the treatment of castrate-resistant
, asymptomatic metastatic prostate cancer which
achieved global sales of approximately 215
million in 2011. Over the forecast period,
numerous vaccines are anticipated to be approved
over a range of indications including the
commonly diagnosed lung and colorectal cancer
types. All of these vaccines have been shown to
improve patient survival, some by a few months,
others by years. The high anticipated price tag
of these vaccines will be a barrier of market
growth. However, due to the fact that numerous
vaccines are anticipated to be approved across a
range of highly diagnosed indications, GBI
Research believes the global market does have the
potential to grow to a value of 7.8 billion by
2019.
3
Description


Scope - The report analyzes treatment usage
patterns, variation in vaccine type and pipeline
and market forecasts across indications for
cancer vaccines. - A brief introduction into
cancer, its relation with the immune system, and
a detailed outline of the 8 different types of
cancer vaccines being developed, including their
strengths and weaknesses. - An analysis of
Provenge, the only currently marketed therapeutic
cancer vaccines, including recent sales figures
and potential future competitors of Provenge. - A
statistical analysis of clinical trial duration
and size by phase and by vaccine type. - An in
depth forecast model for each indication for
which a vaccine is anticipated to be approved
throughout the forecast period. Each model is
based on the anticipated market performance of
the vaccines to be approved for that
indication. - A detailed discussion of the
drivers and barriers for this novel market.
4
Description

Reasons to buy Primarily, the report will allow
clients to gain a strong understanding of RA,
helping to identify and clarify market
opportunities and the competitive environment. It
will also allow you to - - Understand the RA
pipeline and the key trends in the current
product development landscape - Observe detailed
profiles for the promising pipeline products,
including revenue forecasts, and gain an insight
into how they are likely to compete in the
market, and what their main competitors will be -
Follow the trends in RA clinical trial size and
duration in relation to industry averages and
assess the potential risk of future developmental
programs for RA therapeutics, depending on the
mechanism of action, by considering the recorded
clinical trial failure rates - Observe the
potential growth patterns expected for the RA
market over the forecast period, and identify
which countries are expected to make the biggest
contribution to this growth.
5
Table of Contents

• 1 Table of Contents
• 2 Introduction
• 2.1 Cancer Epidemiology
• 2.2 Disease Initiation and Propagation
• 2.3 Symptoms
• 2.3.1 Symptoms of Lung Cancer
• 2.3.2 Symptoms of Prostate Cancer
• 2.3.3 Symptoms of Colorectal Cancer
• 2.3.4 Symptoms of Breast Cancer
• 2.3.5 Symptoms of Melanoma
• 2.3.6 Symptoms of Stomach Cancer
• 2.4 Current Treatment and Management
• 2.4.1 Active Surveillance or the Wait-and
  See Approach
• 2.4.2 Surgery
• 2.4.3 Radiation Therapy
• 2.4.4 Chemotherapy

6
Table of Contents

• 3 Marketed Products
• 4 Product Pipeline
• 5 Forecasting
• 6 Appendix
• For inquiry, kindly contact at
• http//www.reportsandintelligence.com/enquire-abou
  t-report/132374
• To check table of contents of the research, Visit
  _at_ http//www.reportsandintelligence.com/therapeut
  ic-cancer-vaccines-to-2019-pipeline-indicates-safe
  r-treatments-and-extended-patient-survival-though-
  high-prices-may-limit-uptake-market/table-of-conte
  nts

7

FOR MORE DETAILS
Visit us at
http//www.reportsandintelligence.com/therapeutic-
cancer-vaccines-to-2019-pipeline-indicates-safer-t
reatments-and-extended-patient-survival-though-hig
h-prices-may-limit-uptake-market
Stay With Us
TELEPHONE Direct 1 [phone] Toll Free
1 [phone]E-MAIL sales_at_reportsandintellig
ence.com
5933 NE Win Sivers Drive,205, Portland, OR
97220United States